Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases

Int J Antimicrob Agents. 2005 May;25(5):414-8. doi: 10.1016/j.ijantimicag.2004.12.005.

Abstract

We evaluated retrospectively, 10 MRSA meningitis cases in our hospital that occurred between January 1999 and June 2004. All were post-neurosurgical and were considered to have hospital-acquired meningitis. Fever, leukocytosis, variable conscious levels were the most common findings. Six patients were treated with regimens including teicoplanin, and four with vancomycin. Mean duration of treatment was 23.5+/-18.8 days (range, 3-60 days). One patient died. In cases of MRSA meningitis, intravenous vancomycin is the mainstay of therapy. However, six of these 10 patients were successfully treated with regimens including teicoplanin, suggesting that this agent may be an alternative to vancomycin in the therapy of these cases.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Meningitis, Bacterial / drug therapy*
  • Meningitis, Bacterial / microbiology*
  • Methicillin Resistance* / genetics
  • Microbial Sensitivity Tests
  • Middle Aged
  • Postoperative Complications
  • Retrospective Studies
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology*
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / genetics
  • Teicoplanin / pharmacology
  • Teicoplanin / therapeutic use
  • Vancomycin / pharmacology
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Teicoplanin
  • Vancomycin